22nd Sep 2015 10:11
LONDON (Alliance News) - Biopharmaceutical company Biofrontera AG on Tuesday said it has received results of trials conducted on its Ameluz skin cancer treatment on actinic keratosis.
Actinic keratosis is a skin condition caused by long-term sun exposure.
Patients treated with a combination of Ameluz and BF-RhodoLED, Biofrontera's medical device, were completely cleared of all signs of the condition after the first treatment cycle in 61.8% of cases, while patients with remaining lesions were cleared in 90.9% of patients following a repeat treatment cycle.
Biofrontera said the results demonstrate the sustainability of the skin rejuvenation effect offered by Ameluz.
Shares in Biofrontera were untraded in London on Tuesday, having last traded at 195.50 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L